News Release 2014
-
- December 1, 2014
- Release of Flutiform® 50 Aerosol - 120 inhalations, Flutiform® 125 Aerosol - 120 inhalations , a combination drug for asthma treatment
-
- November 27, 2014
- Signing of Co-Marketing Agreement on Investigational Antiallergic Agent, Desloratadine for Japan
-
- November 4, 2014
- Summary of consolidated financial results (November 4, 2014)
-
- November 4, 2014
- Consolidated Financial Results (For the Second Quarter Ended september 30,2014)- Supplementary Information
-
- October 10, 2014
- Kyorin Pharmaceutical and R-Pharm Reach Agreement in Russia and neighboring nations for Activities Related to the Development and Marketing of Imidafenacin
-
- September 10, 2014
- EISAI AND KYORIN ENTER INTO AGREEMENT CONCERNING COMPOUND LIBRARY USE FOR THE DEVELOPMENT OF NEW ANTIBACTERIAL AGENTS
-
- July 29, 2014
- Summary of Consolidated Financial Results (For the First Quarter Ended June 30, 2014) [Japanese Standard]
-
- July 22, 2014
- Kyorin signed a License Agreement with Merck on Vibegron for Overactive Bladder in Japan
-
- July 1, 2014
- Gene-Therapy Product for the Treatment of Malignant Pleural Mesothelioma adopted as Next generation Technology Transfer Program (NexTEP) by JST
-
- May 9, 2014
- Summary of Consolidated Financial Results (For the fiscal year ended March 31, 2014) [Japanese Standard]
-
- February 4, 2014
- Third Quarter Consolidated Financial Results for the Ending Fiscal Year March 31, 2014
-
- February 4, 2014
- Summary of Consolidated Financial Results(For the Third Quarter Ended December 31, 2013) [Japanese Standard]
